Literature DB >> 32521091

High-Resolution Nerve Ultrasound to Assess Nerve Echogenicity, Fascicular Count, and Cross-Sectional Area Using Semiautomated Analysis.

Donata Gamber1, Jeremias Motte1, Antonios Kerasnoudis1, Min-Suk Yoon2, Ralf Gold1, Kalliopi Pitarokoili1, Anna Lena Fisse1.   

Abstract

BACKGROUND AND
PURPOSE: Little is known about echogenicity and fascicular structure observed in high-resolution nerve ultrasound (HRUS) in both healthy subjects and patients with peripheral nerve disease. The aim of this study was to evaluate the reliability of echogenicity, fascicle count, and fascicle size analysis, to create standard values and compare these parameters to patients with chronic inflammatory demyelinating polyneuropathy (CIDP).
METHODS: Median, ulnar, radial, tibial, and fibular nerve of 79 healthy subjects and patients were scanned by one examiner using HRUS. Image analysis regarding echogenicity, fascicle count, and fascicle cross-sectional area (CSA) was performed by two independent raters semiautomatically using ImageJ. Pearson correlation coefficient r reflected interrater reliability (IR), and intraclass correlation coefficient (ICC) determined intrarater reliability (IAR). Results of healthy subjects were compared to 20 patients with CIDP by analysis of variance.
RESULTS: IR was very good for echogenicity (r = .9) and good for fascicle count and size of the largest fascicle (r = .64/.56). IAR was very good for all three parameters (ICC = .9/.83/.74). Healthy subjects had a wide range of values. CIDP patients were in range of healthy subjects. Clinically progressive CIDP patients (defined as an increase in Overall Disability Sum Score by ≥1 point) had a lower fraction of black than healthy controls and stable CIDP patients (P < .001).
CONCLUSION: Semiautomated evaluation of echogenicity, fascicle count, and fascicle CSA is reliable. Cutoff values to differentiate between healthy persons and CIDP do not exist. Echogenicity is useful for detecting clinically progressive CIDP patients and should be used in clinical context or intraindividual course.
© 2020 The Authors. Journal of Neuroimaging published by Wiley Periodicals LLC on behalf of American Society of Neuroimaging.

Entities:  

Keywords:  Chronic inflammatory demyelinating polyneuropathy; echogenicity; fascicle; high-resolution nerve ultrasound; reliability

Mesh:

Year:  2020        PMID: 32521091     DOI: 10.1111/jon.12717

Source DB:  PubMed          Journal:  J Neuroimaging        ISSN: 1051-2284            Impact factor:   2.486


  5 in total

1.  Nerve Echogenicity in Polyneuropathies of Various Etiologies-Results of a Retrospective Semi-Automatic Analysis of High-Resolution Ultrasound Images.

Authors:  Anke Erdmann; Jeremias Motte; Jil Brünger; Thomas Grüter; Ralf Gold; Kalliopi Pitarokoili; Anna Lena Fisse
Journal:  Diagnostics (Basel)       Date:  2022-05-28

2.  Nerve Imaging, Electrodiagnostics, and Clinical Examination - Three Musketeers to Differentiate Polyneuropathies.

Authors:  Natalie Winter; Alexander Grimm
Journal:  Neurotherapeutics       Date:  2022-03-07       Impact factor: 6.088

3.  High-Resolution Nerve Ultrasound Abnormalities in POEMS Syndrome-A Comparative Study.

Authors:  Marc Dörner; Mihai Ceanga; Frank Schreiber; Jan-Hendrik Stahl; Cornelius Kronlage; Julia Wittlinger; Magdalena Kramer; Sophia Willikens; Stefanie Schreiber; Alexander Grimm; Natalie Winter
Journal:  Diagnostics (Basel)       Date:  2021-02-09

Review 4.  Comprehensive approaches for diagnosis, monitoring and treatment of chronic inflammatory demyelinating polyneuropathy.

Authors:  Anna Lena Fisse; Jeremias Motte; Thomas Grüter; Melissa Sgodzai; Kalliopi Pitarokoili; Ralf Gold
Journal:  Neurol Res Pract       Date:  2020-12-08

Review 5.  Nerve Ultrasound as Helpful Tool in Polyneuropathies.

Authors:  Magdalena Kramer; Alexander Grimm; Natalie Winter; Marc Dörner; Kathrin Grundmann-Hauser; Jan-Hendrik Stahl; Julia Wittlinger; Josua Kegele; Cornelius Kronlage; Sophia Willikens
Journal:  Diagnostics (Basel)       Date:  2021-01-31
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.